References

Bloody diarrhoea and clinically suspected or confirmed Shiga toxin-producing Eschericia coli (STEC) infections
National
SIGN toolkit logo
  1. https://www.publichealthscotland.scot/publications/public-health-management-of-shiga-toxin-producing-escherichia-coli-stec-infection/public-health-management-of-shiga-toxin-producing-escherichia-coli-stec-infection-version-2/overview/
  2. Tarr PI, Gordon CA, Chandler WL. Shiga-toxin-producing Escherichia coli and haemolytic uraemic syndrome. Lancet 2005; 365(9464):1073-86.
  3. Penningtonn, TH (2010). Escherichia coli O157. The Lancet 2010; 376(9750): 1428- 1435.
  4. Dundas S, Todd WT, Stewart AI, Murdoch PS, Chaudhuri AK, Hutchinson SJ. The central Scotland Escherichia coli O157:H7 outbreak: risk factors for the hemolytic uremic syndrome and death among hospitalized patients. Clin Infect Dis 2001; 33(7):923-31.
  5. Byrne L, Jenkins C, Launders N, Elson R, Adak GK. (2015). The epidemiology, microbiology and clinical impact of shiga toxin-producing escherichia coli in england, 2009-2012. Epidemiology and Infection, 143(16), 3475-3487.
  6. Brandt JR, Fouser LS, Watkins SL, Zelikovic I, Tarr PI, Nazar-Stewart V, et al. Escherichia coli O 157:H7-associated hemolytic-uremic syndrome after ingestion of contaminated hamburgers. J Pediatr. 1994;125(4):519-26.
  7. Wong CS, Mooney JC, Brandt JR, Staples AO, Jelacic S, Boster DR, Watkins SL, Tarr PI. Risk factors for the hemolytic uremic syndrome in children infected with Escherichia coli O157:H7: a multivariable analysis. Clin Infect Dis. 2012 Jul;55(1):33- 41. doi: 10.1093/cid/cis299. Epub 2012 Mar 19.
  8. Mody RK, Luna-Gierke RE, Jones TF, Comstock N, Hurd S, Scheftel J, Lathrop S, Smith G, Palmer A, Strockbine N, Talkington D, Mahon BE, Hoekstra RM, Grif_n PM. Infections in pediatric postdiarrheal hemolytic uremic syndrome: factors associated with identifying shiga toxin-producing Escherichia coli. Arch Pediatr Adolesc Med. 2012 Oct;166(10):902-9.
  9. Lopez EL, Contrini MM, Glatstein E, Ayala SG, Santoro R, Ezcurra G, Teplitz E, Matsumoto Y, Sato H, Sakai K, Katsuura Y, Hoshide S, Morita T, Harning R, Brookman S. An epidemiologic surveillance of Shiga-like toxin-producing Escherichia coli infection in Argentinean children: risk factors and serum Shiga-like toxin 2 values. Pediatr Infect Dis J. 2012 Jan;31(1):20-4.
  10. Zoufaly A, Cramer JP, Vettorazzi E, Sayk F, Bremer JP, Koop I, de Weerth A, Schmiedel S, Jordan S, Fraedrich K, Asselborn NH, Nitschke M, Neumann-Grutzeck C, Magnus T, Ruther C, Fellermann K, Stahl RK, Wegscheider K, Lohse AW. Risk factors for development of hemolytic uremic syndrome in a cohort of adult patients with STEC 0104:H4 infection. PLoS One. 2013;8(3):e59209.
  11. Tajiri H, Nishi J, Ushijima K, Shimizu T, Ishige T, Shimizu M, Tanaka H,Brooks S. A role for fosfomycin treatment in children for prevention of haemolytic-uraemic syndrome accompanying Shiga toxin-producing Escherichia coli infection. Int J Antimicrob Agents. 2015 Nov;46(5):586-9
  12. Grisaru S. Management of hemolytic-uremic syndrome in children. Int J Nephrol Renovasc Dis. 2014 Jun 12;7:231-9.
  13. Ardissino G, Tel F, et al.Early Volume Expansion and Outcomes of Hemolytic Uremic Syndrome. Pediatrics. 2015 Dec 7. pii:peds.2015-2153.
  14. Keene WE, McAnulty JM, Hoesly FC, Williams LP, Jr., Hedberg K, Oxman GL, et al. A swimming-associated outbreak of hemorrhagic colitis caused by Escherichia coli O157:H7 and Shigella sonnei. N Engl J Med. 1994;331(9):579-84.
  15. Public Health England (PHE) Surrey Independent Investigation Committee (2010) Review of the major outbreak of E. coli O157 in Surrey, 2009 - Report of the Independent Investigation Committee June 2010. Available from: https://gov.uk/government/publications/escherichia-coli-e-coli-o157-report-and-recommendations-from-2009-godstone-incident
  16. European Centre for Disease Prevention and Control. Systematic review on the incubation and infectiousness/shedding period of communicable diseases in children. Stockholm: ECDC; 2016.
  17. European Food Safety Authority, European Centre for Disease Prevention and Control. The European Union Summary Report on Trends and Sources of Zoonoses, Zoonotic Agents and Food-borne Outbreaks in 2010. EFSA Journal 2012; 10(3):2597. http://www.efsa.europa.eu/en/search/doc/2597.pdf.
  18. Snedeker KG, Shaw DJ, Locking ME, Prescott RJ. Primary and secondary cases in Escherichia coli O157 outbreaks: a statistical analysis. BMC Infect Dis. 2009 Aug 28;9:144. doi: 10.1186/1471-2334-9-144.
  19. Wong CS, Jelacic S, Habeeb RL, Watkins SL, Tarr PI. The risk of the hemolyticuremic syndrome after antibiotic treatment of Escherichia coli O157:H7 infections. N Engl J Med 2000;342(26):1930-6.
  20. Smith KE, Wilker PR, Reiter PL, Hedican EB, Bender JB, Hedberg CW. Antibiotic treatment of Escherichia coli O157 infection and the risk of hemolytic uremic syndrome, Minnesota. Pediatr Infect Dis J. 2012 Jan;31(1):37-41.
  21. Piercefield EW, Bradley KK, Coffman RL, Mallonee SM. Hemolytic Uremic Syndrome After an Escherichia coli O111 Outbreak. Arch Intern Med. 2010 Oct 11;170(18):1656- 63.
  22. Hickey CA, Beattie TJ, et al. Early volume expansion during diarrhoea and relative nephroprotection during subsequent hemolytic uremic syndrome. Arch Pediatr Adolesc Med. 2011 Oct;165(10):884-9
  23. Ake JA, et al. Relative nephroprotection during Escherichia coli O157:H7 infections: association with intravenous volume expansion. Pediatrics. 2005, Jun;115(6):e673-80
  24. Balestracci A, Martin SM, Toledo I, Alvarado C, Wainsztein RE. Dehydration at admission increased the need for dialysis in hemolytic uremic syndrome children. Pediatr Nephrol. 2012 Aug;27(8):1407-10.
  25. Ojeda JM, Kohout I, Cuestas E. Dehydration upon admission is a risk factor for incomplete recovery of renal function in children with haemolytic uremic syndrome. Nefrologia. 2013;33(3):372-6.
  26. Bell BP, Goldoft M, Griffin PM, Davis MA, Gordon DC, Tarr PI, et al. A multistate outbreak of Escherichia coli O157:H7-associated bloody diarrhoea and hemolytic uremic syndrome from hamburgers. The Washington experience. JAMA 1994;272(17):1349-53.
  27. Health Protection Agency. The management of acute bloody diarrhoea potentially caused by verocytotoxin-producing Escherichia coli in children. 2011.
  28. Murray MD, Brater DC. Renal toxicity of the nonsteroidal anti-inflammatory drugs. Annu Rev Pharmacol Toxicol 1993;33:435-65.
  29. Phillips B, Tyerman K, Whiteley SM. Use of antibiotics in suspected haemolytic-uraemic syndrome. BMJ 2005;330(7488):409-10.
  30. Safdar N, Said A, Gangnon RE, Maki DG. Risk of hemolytic uremic syndrome after antibiotic treatment of Escherichia coli O157:H7 enteritis: a meta-analysis. JAMA 2002;288(8):996-1001.
  31. Dundas S, Todd WT, Neill MA, Tarr PI. Using antibiotics in suspected haemolytic-uremic syndrome: antibiotics should not be used in Escherichia coli O157:H7 infection. BMJ 2005;330(7501):1209; author reply 1209.
  32. Agger M, Scheutz F, Villumsen S, Mølbak K, Petersen AM. Antibiotic treatment of verocytotoxin-producing Escherichia coli (STEC) infection: a systematic review and a proposal. J Antimicrob Chemother. 2015 Sep;70(9):2440-6.
  33. Sutherland SM, Zappitelli M, Alexander SR, Chua AN, Brophy PD, Bunchman TE, Hackbarth R, Somers MJ, Baum M, Symons JM, Flores FX, Benfield M, Askenazi D, Chand D, Fortenberry JD, Mahan JD, McBryde K, Blowey D, Goldstein SL. Fluid overload and mortality in children receiving continuous renal replacement therapy: the prospective pediatric continuous renal replacement therapy registry. Am J Kidney Dis. 2010 Feb;55(2):316-25.
  34. Silviu Grisaru, Melissa A. Morgunov, Susan M. Samuel, Julian P. Midgley, Andrew W. Wade, James B. Tee, and Lorraine A. Hamiwka. Acute Renal Replacement Therapy in Children with Diarrhea-Associated Hemolytic Uremic Syndrome: A Single Center 16 Years of Experience. Int J Nephrol. 2011; 2011: 930539. Published online 2011 May 26.
  35. Garg AX, Suri RS, Barrowman N, et al. Long-term renal prognosis of diarrhoea-associated hemolytic uremic syndrome: a systematic review, meta-analysis, and meta-regression. JAMA. 2003;290(10):1360–1370.
  36. De Petris L, Gianviti A, Giordano U, Calzolari A, Tozzi AE, Rizzoni G. Blood pressure in the long-term follow-up of children with hemolytic uremic syndrome. Pediatr Nephrol 2004;19(11):1241-4.
  37. Derad I, Obermann B, Katalinic A, Eisemann N, Knobloch JK, Sayk F, Wellhöner P, Lehnert H, Solbach W, Süfke S, Steinhoff J, Nitschke M. Hypertension and mild chronic kidney disease persist following severe haemolytic uraemic syndrome caused by Shiga toxin-producing Escherichia coli O104:H4 in adults. Nephrol Dial Transplant. 2015 Jul 14.
  38. Alejandra Rosales, Johannes Hofer, Lothar-Bernd Zimmerhackl,a Therese C. Jungraithmayr, Magdalena Riedl, Thomas Giner, Alexander Strasak, Dorothea Orth-Höller, Reinhard Wűrzner, and Helge Karch, for the German-Austrian HUS Study Group. Need for Long-term Follow-up in Enterohemorrhagic Escherichia coli– Associated Hemolytic Uremic Syndrome Due to Late-Emerging Sequelae. Clin Infect Dis 2012 May 12;54(10):1413-21.
  39. Loos S, Ahlenstiel T, Kranz B, Staude H, Pape L, Härtel C, Vester U, Buchtala L, Benz K, Hoppe B, Beringer O, Krause M, Müller D, Pohl M, Lemke J, Hillebrand G, Kreuzer M, König J, Wigger M, Konrad M, Haffner D, Oh J, Kemper MJ. An outbreak of Shiga toxin-producing Escherichia coli O104:H4 hemolytic uremic syndrome in Germany: presentation and short-term outcome in children. Clin Infect Dis. 2012 Sep;55(6):753-9.
  40. Michael M, Elliott EJ, Craig JC, Ridley G, Hodson EM. Interventions for hemolytic uremic syndrome and thrombotic thrombocytopenic purpura: a systematic review of randomized controlled trials. Am J Kidney Dis. 2009 Feb;53(2):259-72. Also reported in: M Michael, EJ Elliott, GF Ridley, EM Hodson, JC Craig. Interventions for haemolytic uraemic syndrome and thrombotic thrombocytopenic purpura. Cochrane Database Syst Rev, 1 (2009) CD003595.
  41. Pape L, Hartmann H, Bange FC, Suerbaum S, Bueltmann E, Ahlenstiel-Grunow T. Eculizumab in Typical Hemolytic Uremic Syndrome (HUS) With Neurological Involvement. Medicine (Baltimore). 2015 Jun;94(24):e1000.
  42. Delmas Y, Vendrely B, Clouzeau B, Bachir H, Bui HN, Lacraz A, Hélou S, Bordes C, Reffet A, Llanas B, Skopinski S, Rolland P, Gruson D, Combe C. Outbreak of Escherichia coli O104:H4 haemolytic uraemic syndrome in France: outcome with eculizumab. Nephrol Dial Transplant. 2014 Mar;29(3):565-72.
  43. Kielstein JT, Beutel G, et al. Best supportive care and therapeutic plasma exchange with or without eculizumab in Shiga-toxin-producing E. coli O104:H4 induced haemolytic-uraemic syndrome: an analysis of the German STEC-HUS registry. Nephrol Dial Transplant. 2012 Oct;27(10):3807-15.
  44. Menne J, Nitschke M, et al. Validation of treatment strategies for enterohaemorrhagic Escherichia coli O104:H4 induced haemolytic uraemic syndrome: case-control study. BMJ. 2012 Jul 19;345:e4565.
  45. Kohli HS, Chaudhuri AK, Todd WT, Mitchell AA, Liddell KG. A severe outbreak of E.coli O157 in two psychogeriatric wards. J Pub Health Med 1994; 16: 11-5. ld LH at al. L. Hannah Gould. The Emerging Infections Program FoodNet Working Group. Hemolytic Uremic Syndrome and Death in Persons with Escherichia coli O157:H7 Infection, Foodborne Diseases Active Surveillance Network Sites, 2000–2006. Clin Infect Dis (2009) 49 (10): 1480-1485.